Context Therapeutics Inc. (NASDAQ:CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context Therapeutics presented a Trial in Progress poster for its Phase 1 clinical trial ...
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclib OPERA-01 trial-in-progress poster to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results